Preview

Rational Pharmacotherapy in Cardiology

Advanced search

Damage to the Cardiovascular System in Patients with SARS-CoV-2 Coronavirus Infection. Part 1: Predictors of the Development of an Unfavorable Prognosis

https://doi.org/10.20996/1819-6446-2021-11-03

Full Text:

Abstract

Aim. To evaluate the effect of sinus tachycardia and reduced left ventricular ejection fraction (LVEF) on the prognosis of patients with a verified diagnosis of a new coronavirus infection SARS-CoV-2.

Material and methods. The study included 1,637 patients with a verified diagnosis of a new coronavirus infection SARS-CoV-2. The average age of the patients was 58.8±16.1 years. More than half of the patients admitted to the hospital had a history of cardiovascular diseases: hypertension was diagnosed in 915 (56%) patients, coronary artery disease – in 563 (34%), chronic heart failure – in 410 (25%). 294 (17.9%) patients suffered from diabetes mellitus. The unfavorable course of new coronavirus infection was assessed by the fact of being in the intensive care unit (ICU), the use of mechanical ventilation and death.

Results. An unfavorable course of coronavirus infection was observed in 160 (9.8%) patients. Statistical analysis revealed that 341 (20.8%) patients with COVID-19 were diagnosed with sinus tachycardia, which required the appointment of pulse-reducing therapy. The occurrence of sinus tachycardia in patients with COVID-19 significantly increased the risk of death (odds ratio [OR] 1.248, confidence interval [CI] 1.038-1.499, p=0.018), increased the likelihood of mechanical ventilation use (OR 1.451, CI 1.168-1.803, p<0.001) and stay in the ICU (OR 1.440, CI 1.166-1.778, p<0.001).

In 97 (5.9%) patients during hospital stay during echocardiography, a decrease in LVEF of less than 50% was diagnosed. A decrease in myocardial contractile function in patients with COVID-19 with high reliability increased the risk of death (OR 1.744, CI 1.348-2.256, p<0.001), increased the likelihood of using the mechanical ventilation (OR 1.372, CI 1.047-1.797, p=0.022) and stay in the ICU (OR 1.360, CI 1.077-1.716, p=0.010).

Conclusion. The appearance of sinus tachycardia and reduced LVEF are in dependent predictors of the unfavorable course of COVID-19 in relation to factors such as death, the use of mechanical ventilation and the stay of patients in the ICU. Early pharmacological correction of cardiovascular lesions should be one of the goals of the management theese patients.

About the Authors

V. I. Podzolkov
I.M. Sechenov First Moscow State Medical University (Sechenov University)
Russian Federation

Valery I. Podzolkov.

Moscow.

eLibrary  SPIN  8683-2155



A. I. Tarzimanova
I.M. Sechenov First Moscow State Medical University (Sechenov University)
Russian Federation

Aida I. Tarzimanova.

Moscow.

eLibrary  SPIN  2685-4078



A. E. Bragina
I.M. Sechenov First Moscow State Medical University (Sechenov University)
Russian Federation

Anna E. Bragina.

Moscow.

eLibrary SPIN 3753-5539



I. I. Shvedov
I.M. Sechenov First Moscow State Medical University (Sechenov University)
Russian Federation

Ilia I. Shvedov.

Moscow.



E. E. Bykova
I.M. Sechenov First Moscow State Medical University (Sechenov University)
Russian Federation

Ekaterina E. Bykova.

Moscow.

eLibrary SPIN 8932-8731



A. A. Ivannikov
I.M. Sechenov First Moscow State Medical University (Sechenov University)
Russian Federation

Alexander A. Ivannikov.

Moscow.



L. V. Vasilyeva
I.M. Sechenov First Moscow State Medical University (Sechenov University)
Russian Federation

Lubov V. Vasilyeva.

Moscow.

eLibrary SPIN 9111-1333



References

1. Shlyakho EV, Konradi AO, Arutyunov GP, et al. Guidelines for the diagnosis and treatment of circulatory diseases in the context of the COVID-19 pandemic. Russian Journal of Cardiology. 2020;25(3):3801 (In Russ.) DOI:10.15829/1560-4071-2020-3-3801.

2. Xiong TY, Redwood S, Prendergast B, Chen M. Coronaviruses and the cardiovascular system: acute and long-term implications. Eur Heart J. 2020;41(19):1798-800. DOI:10.1093/eurheartj/ehaa231.

3. Chen Y, Guo Y, Pan Y, et al. Structure analysis of the receptor binding of 2019-nCoV. Biochem Biophys Res Commun. 2020;525(1):135-40. DOI:10.1016/j.bbrc.2020.02.071.

4. Tan WSD, Liao W, Zhou S, et al. Targeting the renin-angiotensin system as novel therapeutic strategy for pulmonary diseases. Curr Opin Pharmacol. 2018;40:9-17. DOI:10.1016/j.coph.2017.12.002.

5. Mareev VYu, Orlova YaA, Plisyk AG, et al. Results of Open-Label non-Randomized Comparative Clinical Trial: “BromhexIne and Spironolactone for CoronаvirUs Infection requiring hospiTalization (BISCUIT). Kardiologiia. 2020;60(11):4-15 (In Russ.) DOI:10.18087/cardio.2020.11.n1440.

6. Cadegiani FA, Wambier CG, Goren A. Spironolactone: An Anti-androgenic and Anti-hypertensive Drug That May Provide Protection Against the Novel Coronavirus (SARS-CoV-2) Induced Acute Respiratory Distress Syndrome (ARDS) in COVID-19. Front Med (Lausanne). 2020;7:453. DOI:10.3389/fmed.2020.00453

7. Haenel J. [The effect of aldactone on advanced respiratory insufficiency (respiratory acidosis) in chronic corpulmonale]. Munch Med Wochenschr. 1963;105:2179-85 (In German).

8. Lieber GB, Fernandez X, Mingo GG, et al. Mineralocorticoid receptor antagonists attenuate pulmonary inflammation and bleomycin-evoked fibrosis in rodent models. Eur J Pharmacol. 2013;718(1-3):290-8. DOI:10.1016/j.ejphar.2013.08.019.

9. 2019 ESC Guidelines for the management of patients with supraventricular tachycardiaThe Task Force for the management of patients with supraventricular tachycardia of the European Society of Cardiology (ESC). Eur Heart J. 2020;41(5):655-720 DOI:10.1093/eurheartj/ehz467.

10. Groß S, Jahn C, Cushman S, et al. SARS-CoV-2 receptor ACE2-dependent implications on the cardiovascular system: From basic science to clinical implications. J Mol Cell Cardiol. 2020;144:47-53. DOI:10.1016/j.yjmcc.2020.04.031

11. Clinckemalie L, Spans L, Dubois V, et al. Androgen regulation of the TMPRSS2 gene and the effect of a SNP in an androgen response element. Mol Endocrinol. 2013;27(12):2028-40. DOI:10.1210/me.2013-1098.

12. Zhou H, Xi D, Liu J, et al. Spirolactone provides protection from renal fibrosis by inhibiting the endothelial-mesenchymal transition in isoprenaline-induced heart failure in rats. Drug Des Devel Ther. 2016;10:1581-8. DOI:10.2147/DDDT.S100095.

13. Grinevich VB, Gubonina IV, Doshchitsin VL, et al. Management of patients with comorbidity during novel coronavirus (COVID-19) pandemic. National Consensus Statement 2020. Cardiovascular Therapy and Prevention. 2020;19(4):2630. (In Russ.) DOI:10.15829/1728-8800-2020-2630.

14. Ministry of Health of the Russian Federation “Temporary guidelines” Prevention, diagnosis and treatment of new coronavirus infection (COVID-19) “Version 13 (14.10.2021)” [cited 2021 Sep 15]. Available from: https://static-0.minzdrav.gov.ru/system/attachments/attaches/000/058/211/original/BMP-13.pdf (In Russ.)

15. Mani VR, Kalabin A, Valdivieso SC, et al. New York Inner City Hospital COVID-19 Experience and Current Data: Retrospective Analysis at the Epicenter of the American Coronavirus Outbreak. J Med Internet Res. 2020;22(9):20548. DOI:10.2196/20548.

16. Wang Y, Chen L, Wang J, et al. Electrocardiogram analysis of patients with different types of COVID-19. Ann Noninvasive Electrocardiol. 2020;25(6):12806. DOI: 10.1111/anec.12806.

17. Podzolkov VI, Bragina AE, Tarzimanova AI, et al. Post-COVID Syndrome and Tachycardia: Theoretical Base and Treatment Experience. Rational Pharmacotherapy in Cardiology. 2021;17(2):256-62. (In Russ.) DOI:10.20996/1819-6446-2021-04-08.

18. Knuuti J, Wijns W, Saraste A, et al. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. The Task Force for the diagnosis and management of chronic coronary syndromes of the European Society of Cardiology (ESC). Eur Heart J. 2020;41(44):4242. DOI:10.1093/eurheartj/ehz425.

19. Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2016;37(27):2129-200. DOI:10.1093/eurheartj/ehw128.

20. Tahir F, Bin AT, Majid Z, et al. Ivabradine in Postural Orthostatic Tachycardia Syndrome: A Review of the Literature. Cureus. 2020;12(4):7868. DOI:10.7759/cureus.7868.


Review

For citation:


Podzolkov V.I., Tarzimanova A.I., Bragina A.E., Shvedov I.I., Bykova E.E., Ivannikov A.A., Vasilyeva L.V. Damage to the Cardiovascular System in Patients with SARS-CoV-2 Coronavirus Infection. Part 1: Predictors of the Development of an Unfavorable Prognosis. Rational Pharmacotherapy in Cardiology. 2021;17(6):825-830. (In Russ.) https://doi.org/10.20996/1819-6446-2021-11-03

Views: 109


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 1819-6446 (Print)
ISSN 2225-3653 (Online)